Cartesian Therapeutics (RNAC) Return on Capital Employed (2016 - 2026)

Cartesian Therapeutics (RNAC) has 11 years of Return on Capital Employed data on file, last reported at 53.54% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 53.54%, down 4066.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 53.54% (down 4066.0% YoY), and the FY2025 annual result was 40.88%, down 2823.0% from the prior year.
• Return on Capital Employed slipped to 53.54% in Q1 2026 per RNAC's latest filing, from 44.87% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 20.09% in Q2 2022 and troughed at 62.92% in Q4 2023.
• A 5-year average of 20.02% and a median of 15.78% in 2024 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2022 and 2023: Return on Capital Employed surged 6396 bps in 2022, then tumbled 7397 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 9.89% in 2022, then tumbled by 736 bps to 62.92% in 2023, then surged by 83 bps to 10.4% in 2024, then tumbled by 332 bps to 44.87% in 2025, then decreased by 19 bps to 53.54% in 2026.
• Business Quant data shows RNAC's Return on Capital Employed at 53.54% in Q1 2026, 44.87% in Q4 2025, and 24.93% in Q3 2025.